Medivir AB Release: Results From a Phase IIa Study Evaluating Simeprevir and Sofosbuvir in Prior Null Responder Hepatitis C Patients Have Been Presented at CROI

Published: Mar 06, 2013

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced that interim results from the COSMOS study (Combination Of SiMeprevir and sOfosbuvir in HCV genotype 1 infected patientS) have been presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI) on March 6 in Atlanta, Georgia, USA.

These COSMOS interim results are from the first cohort of a phase IIa study of the investigational protease inhibitor simeprevir (TMC435) administered once daily with Gilead’s investigational nucleotide inhibitor sofosbuvir (GS-7977) with and without ribavirin (RBV) for 12 and 24 weeks in genotype 1 prior null -responder hepatitis C patients with mild to moderate fibrosis (METAVIR F0-2). Simeprevir is jointly developed by Medivir AB and Janssen R&D Ireland, an affiliate of the Janssen Pharmaceutical Companies.

Back to news